American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 810-819 , November 2009

Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)

  • Helen M. Colhoun, MD

      Affiliations

    • University of Dundee, Dundee, Scotland, UK
    • Corresponding Author InformationAddress correspondence to Helen M. Colhoun, MD, Biomedical Research Institute, University of Dundee, Mackenzie Bldg, Kirsty Semple Way, Dundee, DD2 4BF Scotland, UK
    • ,
  • D. John Betteridge, PhD

      Affiliations

    • University College London Hospital, London, UK
    • ,
  • Paul N. Durrington, MD

      Affiliations

    • Cardiovascular Research Group, School of Clinical and Laboratory Sciences, Core Technology Facility, University of Manchester, UK
    • ,
  • Graham A. Hitman, MD

      Affiliations

    • Centre for Diabetes and Metabolic Medicine, Barts and the London School of Medicine and Dentistry, London, UK
    • ,
  • H. Andrew W. Neil, DSc

      Affiliations

    • University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK
    • ,
  • Shona J. Livingstone, MSc

      Affiliations

    • University of Dundee, Dundee, Scotland, UK
    • ,
  • Valentine Charlton-Menys, PhD

      Affiliations

    • Cardiovascular Research Group, School of Clinical and Laboratory Sciences, Core Technology Facility, University of Manchester, UK
    • ,
  • David A. DeMicco, PharmD

      Affiliations

    • Pfizer, New York, NY
    • ,
  • John H. Fuller, FRCP

      Affiliations

    • EURODIAB, Department of Epidemiology and Public Health, Royal Free and University of London Medical School, London, UK
    • ,
  • CARDS Investigators

Received 5 December 2008 ,Accepted 27 March 2009.

References 

  1. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  2. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651
  3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  4. Wanner C, Drechsler C, Krane V. Lipid metabolism in chronic kidney disease: The role of statins in cardiovascular risk. J Ren Nutr. 2007;17:75–78
  5. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  6. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S12–S154
  7. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  8. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  9. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease (A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study). J Clin Pathol. 2004;57:728–734
  10. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  11. Shepherd J, Kastelein JP, Bittner VA, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83:870–879
  12. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol. 2007;2:1131–1139
  13. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol. 2008;51:1448–1454
  14. Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412–424
  15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  16. Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol. 2008;101:975–979
  17. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med. 2006;145:117–124
  18. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809–2816
  19. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): Randomised controlled trial. Lancet. 2005;366:1849–1861
  20. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748–3754
  21. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007;49:373–382
  22. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117–125
  23. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407
  24. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207–S210

 Originally published online as doi: 10.1053/j.ajkd.2009.03.022 on June 22, 2009.

 A list of the CARDS Investigators appears at the end of this article.

 Trial registration: ClinicalTrials.gov; study number: NCT00327418.

PII: S0272-6386(09)00711-2

doi: 10.1053/j.ajkd.2009.03.022

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 810-819 , November 2009

Article Tools

* Image Usage & Resolution